Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2009

View Archived Issues

Alacizumab pegol and carboplatin/paclitaxel combination safe and active in advanced NSCLC

Shareholders of Schering-Plough approve proposed merger with Merck & Co.

MedImmune advances MEDI-573, MEDI-575 and MEDI-547 into phase I

Depomed reports results from phase I study of DM-1992 in Parkinson's disease

Cardiome and Astellas conduct confirmatory Kynapid trial under FDA SPA

Cephalon acquires Arana Therapeutics and its lead biologic ART-621

Biotec to proceed with phase III SBG trial following independent interim analysis

ALX-0081 shows superior preclinical antithrombotic activity compared to marketed antiplatelet drugs

Novel variegin-based class of thrombin inhibitors developed as anticoagulants

Endocyte discloses encouraging preliminary phase II data on EC-145 in advanced lung cancer

Novel small-molecule dimer disruptor inhibits herpesvirus protease activity in vitro

Selective P2Y12 receptor antagonist ASP-1645 displays potent preclinical antithrombotic activity

New series of selective cannabinoid CB2 receptor agonists described as analgesic candidates

Amgen discloses new CDK4 and CDK6 inhibitors for the treatment of cancer

Novartis discovers PI3K inhibitors for cancer treatment

Nicotinic receptor agonists in development at Pfizer for ADHD and other disorders

Abbott describes PAMs of neuronal nicotinic receptors for cognition disorders

Functional Genetics developing TSG101 inhibitors for viral infections

PI3K inhibitors presented by UCB for inflammatory and autoimmune diseases

Selective A2A receptor agonists claimed by PGxHealth for autoimmune conditions

Gene Signal presents phase I safety data for GS-101 eyedrops

Knopp Neurosciences to present phase II results of KNS-760704 in ALS

Label extension for Tracleer approved by the FDA

Array reports phase I results for ARRY-403 in type 2 diabetes

Topline results presented from phase III study of anti-influenza virus agent